Formycon AG Stock
Price
Target price
€43.30
€43.30
-0.810%
-0.35
-0.810%
€100.00
10.05.24 / Tradegate
WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Formycon AG is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Formycon
sharewise wants to provide you with the best news and tools for Formycon, so we directly link to the best financial data sources.
Financials
News
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
EQS-News: Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
EQS-News: Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
EQS-News: Gedeon Richter becomes strategic investor of Formycon via equity investment
EQS-News: Gedeon Richter becomes strategic investor of Formycon via equity investment
EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
EQS-News: Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
EQS-News: Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
EQS-News: Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®
EQS-News: Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®
EQS-News: Formycon announces participation in international Investor Conferences in Q1/2024
EQS-News: Formycon announces participation in international Investor Conferences in Q1/2024
EQS-News: Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration
EQS-News: Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration
EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
EQS-News: Formycon publishes nine-month results for 2023
EQS-News: Formycon publishes nine-month results for 2023